Developing treatments for the approximately 7,000 known rare diseases, particularly the subset classified as ultra-rare, presents profound and often insurmountable…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
Rethinking evidence generation for ultra-rare diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the inherent limitations of traditional…
Read More
Evidence for the Formation of Eta-Prime Mesic Nuclei and Its Implications for the Origin of Mass in the Universe
The fundamental question of why matter possesses mass remains one of the most profound mysteries in modern physics, transcending the…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
Breakthrough in Catalytic Science Reveals Direct Evidence of Bulk Oxygen Spillover in Metal-Support Interfaces
In a landmark study published in the journal Nature on April 15, 2026, a collaborative team of scientists from the…
Read More
Evidence for the Formation of η’-Mesic Nuclei and Its Implications for the Origin of Particle Mass
In a landmark achievement for the field of subatomic physics, an international collaboration of researchers has announced the first experimental…
Read More
Rethinking Evidence Generation for Ultra-Rare Diseases
Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…
Read More
University of Arizona Researchers Identify Evidence of Human Heart Muscle Regeneration in Patients Using Artificial Heart Pumps
A collaborative international research effort led by physician-scientists at the University of Arizona College of Medicine – Tucson’s Sarver Heart…
Read More
